Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Cemiplimab in Resectable NSCLC with PD-L1 ≥50%
NCT07450183Phase 2Not yet recruiting
- Sponsor
- Henry Ford Health
- Start
- Jan 2027
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab in non-small cell lung cancer (NSCLC), sponsored by Henry Ford Health. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07450183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07450183.